Palisade Bio (PALI) Research & Development (2010 - 2026)
Palisade Bio (PALI) posted quarterly Research & Development of $6.0 million for Q1 2026, up 531.58% year-over-year from $950000.0 in Q1 2025, and down 2.8% quarter-over-quarter from $6.2 million in Q4 2025.
Palisade Bio (PALI) Research & Development (2010 - 2026) Analysis & Trends
Palisade Bio (PALI) has reported Research & Development for 17 consecutive years, with $6.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 531.58% year-over-year to $6.0 million; the TTM figure through Mar 2026 stood at $15.2 million (up 95.44% YoY), while the FY2025 annual figure was $10.2 million, up 12.46% from the prior year.
- Research & Development slipped to $6.0 million in Q1 2026 per PALI's latest filing, from $6.2 million in the prior quarter.
- Across five years, Research & Development topped out at $16.0 million in Q3 2024 and bottomed at -$11.8 million in Q4 2024.
- Historically, Research & Development has averaged $2.2 million across 5 years, with a median of $1.9 million in 2022.
- On a YoY basis, Research & Development climbed as much as 660.46% in 2024 and fell as far as 3353.87% in 2024.
- Palisade Bio's Research & Development stood at $2.3 million in 2022, then slumped by 84.55% to $362000.0 in 2023, then slumped by 3353.87% to -$11.8 million in 2024, then soared by 152.41% to $6.2 million in 2025, then dropped by 2.8% to $6.0 million in 2026.
- Business Quant data shows PALI's Research & Development at $6.0 million in Q1 2026, $6.2 million in Q4 2025, and $1.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Palisade Bio | 372.94 Mn | 247.74 Mn | - | 7.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.40 Mn |
| Mar 31, 2026 | 6.00 Mn |
| Dec 31, 2025 | 6.17 Mn |
| Sep 30, 2025 | 1.39 Mn |
| Jun 30, 2025 | 1.68 Mn |
| Mar 31, 2025 | 950,000.00 |
| Dec 31, 2024 | -11.78 Mn |
| Sep 30, 2024 | 16.00 Mn |
| Jun 30, 2024 | 2.63 Mn |
| Mar 31, 2024 | 2.21 Mn |
| Dec 31, 2023 | 362,000.00 |
| Sep 30, 2023 | 2.10 Mn |
| Jun 30, 2023 | 2.18 Mn |
| Mar 31, 2023 | 1.24 Mn |
| Dec 31, 2022 | 2.34 Mn |
| Sep 30, 2022 | 1.93 Mn |
| Jun 30, 2022 | 1.32 Mn |
| Mar 31, 2022 | 959,000.00 |
| Dec 31, 2021 | 800,000.00 |
| Sep 30, 2021 | 624,000.00 |